 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Classification and phylogenic relations of β -lactamases which involved with resistance to broad spectrum β -lactams |
| Language |
J |
| AuthorList |
Yoshichika Arakawa |
| Affiliation |
Department of Bacterial Pathogenesis and Infection Control, National Institute of Infectious Diseases |
| Publication |
J.J.C.M.: 13 (3), 150-161, 2003 |
| Received |
October 28, 2003 |
| Accepted |
|
| Abstract |
Various β -lactamases which hydrolyze broad-spectrum β -lactams have emerged worldwide. TEM-derived and SHV-derived extended-spectrum β -lactamases (ESBLs) which can inactivate oxyimino cephalosporins including ceftazidime and cefotaxime have widely been distributed over almost all geographical areas so far. CTX-M-type β -lactamases which preferentially hydrolyzes cefotaxime and ceftriaxone have also emerged in various regions on the Earth. Moreover, cephamycin-hydrolyzing CMY-type enzymes have widely been isolated from human and animals. Furthermore, carbapenem-inactivating metallo-β -lactamases such as IMP-1 and VIM-2 have already been disseminated in many clinical settings. The emergence and proliferation of these new β -lactamases with broad and extended substrate specificity has become an actual hindrance of chemotherapy. Since the classification and phylogenic relation among β -lactamases have become very complicated, I will try to rearrange and summarize the character and genetic feature of several major β -lactamases which inactivate clinically important broad-spectrum β -lactams. |
| Keywords |
|
|
